Skip to content

Annexon ANNX Operating Income

Operating Income at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$642.9M+8.7%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$46.53M-40.3%
Vor Biopharma logo
Vor BiopharmaVOR
-$35.16M-5.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.7M+2.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$39.05M+12.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%

Other financials

Income statement

See full
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's operating income?
Annexon (ANNX) reported operating income of -$46.05M in Q1 2026.
How has Annexon's operating income changed year-over-year?
Annexon's operating income increased by 19.8% year-over-year, from -$57.41M to -$46.05M.
What is the long-term trend for Annexon's operating income?
Over 4 years (2021 to 2025), Annexon's operating income has grown at a 13.4% compound annual growth rate (CAGR), from -$130.71M to -$216.41M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.